← Back to Search

GABA receptor modulator

Zulresso for Postpartum Psychosis

Phase < 1
Recruiting
Led By Mary Kimmel, MD
Research Sponsored by University of North Carolina, Chapel Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinician diagnosis of affective psychosis or mania
Age 18-45 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to post-treatment day 7
Awards & highlights

Study Summary

This trial will study whether the drug Zulresso is effective in treating postpartum psychosis, a severe form of postpartum depression.

Who is the study for?
This trial is for adult women aged 18-45 who have given birth within the last year and are experiencing postpartum psychosis. They must be able to consent to treatment, not currently pregnant, and without severe kidney or liver issues, significant anemia, untreated thyroid problems, or a history of schizophrenia.Check my eligibility
What is being tested?
The study tests Zulresso (brexanolone) on women with postpartum psychosis to see if it's as effective as it has been for postpartum depression. It's an open-label trial where all participants know they're receiving the actual medication.See study design
What are the potential side effects?
While specific side effects aren't listed here, similar medications can cause dizziness, headache, sleepiness or fatigue. There may also be risks associated with infusion reactions since Zulresso is administered intravenously.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with affective psychosis or mania by a doctor.
Select...
I am between 18 and 45 years old.
Select...
I gave birth within the last 12 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to post-treatment day 7
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to post-treatment day 7 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Positive and Negative Syndrome Scale (PANSS) score
Change in Young Mania Rating Scale (YMRS) score
Secondary outcome measures
Change in Clinical Global Impression Scale (CGI)
Change in Edinburgh Postnatal Depression Scale (EPDS)
Change in Hamilton Rating Scale for Depression (HAM-D)

Side effects data

From 2021 Phase 3 trial • 28 Patients • NCT03665038
25%
Infusion site pain
13%
Nausea
13%
Upper respiratory tract infection
13%
Sedation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Double-Blind Phase: Placebo
Double-Blind Phase: Brexanolone
Open-Label Phase: Brexanolone

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open Label - Active DrugExperimental Treatment1 Intervention
Brexanolone (zulresso) infusion arm. All patients enrolled will receive active treatment with brexanolone.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Brexanolone
FDA approved

Find a Location

Who is running the clinical trial?

University of North Carolina, Chapel HillLead Sponsor
1,503 Previous Clinical Trials
4,187,662 Total Patients Enrolled
Sage TherapeuticsIndustry Sponsor
49 Previous Clinical Trials
11,751 Total Patients Enrolled
Mary Kimmel, MDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill
1 Previous Clinical Trials

Media Library

Brexanolone (GABA receptor modulator) Clinical Trial Eligibility Overview. Trial Name: NCT05314153 — Phase < 1
Postpartum Psychosis Research Study Groups: Open Label - Active Drug
Postpartum Psychosis Clinical Trial 2023: Brexanolone Highlights & Side Effects. Trial Name: NCT05314153 — Phase < 1
Brexanolone (GABA receptor modulator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05314153 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants have been included in the research so far?

"Affirmative. Utilizing clinicaltrials.gov as a source, it is evident that this medical trial commenced on February 23rd 2022 and was updated most recently on March 28th 2022. 10 test subjects are necessary for the study to be conducted at one site only."

Answered by AI

Does this experimental procedure have an age restriction, particularly for those over 30?

"This trial stipulates that participants must fall within the age parameters of 18 and 45."

Answered by AI

For whom would this research be most beneficial?

"The requirements for this clinical trial involve being between 18 and 45 years old as well as having a diagnosed psychotic disorder. Up to 10 people are eligible for participation in the study."

Answered by AI

Are there any vacancies remaining in this clinical experiment?

"Affirmative, clinicaltrials.gov attests to the veracity of this medical study's active recruitment process that started on February 23rd 2022 and has been recently updated as of March 28th 2022. At present, 10 people are needed from a single centre for participation in the trial."

Answered by AI
Recent research and studies
~0 spots leftby Jun 2024